ZDA
AEGR

Zweig-DiMenna Associates’s Aegerion Pharmaceuticals AEGR Stock Holding History

Zweig-DiMenna Associates’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-46,791
Closed -$980K – 349
2014
Q4 		$980K Sell
46,791
-980
-2% -$24.7K 0.04% 138
2014
Q3 		$1.59M Hold
47,771
– – 0.07% 137
2014
Q2 		$1.53M Hold
47,771
– – 0.07% 130
2014
Q1 		$2.21M Sell
47,771
-104,644
-69% -$6.14M 0.13% 112
2013
Q4 		$10.8M Sell
152,415
-268,985
-64% -$20.6M 0.4% 85
2013
Q3 		$36.1M Buy
421,400
+204,710
+94% +$17.4M 1.46% 11
2013
Q2 		$13.7M Buy
+216,690
New +$11.5M 0.55% 74

Other funds holding AEGR

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Zweig-DiMenna Associates's AEGR Position: Q1 2015 in Review

Zweig-DiMenna Associates sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2015, closing a stake of 46,791 shares — an estimated $980K sold.

Zweig-DiMenna Associates first reported a position in AEGR in Q2 2013 and held it in 7 quarters. The position peaked at $36.1M in Q3 2013. 99 funds tracked by Wall St. Rank hold AEGR as of Q1 2015.

  • Zweig-DiMenna Associates reported no remaining Aegerion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 46,791 Aegerion Pharmaceuticals shares in Q1 2015, an estimated $980K.
  • Zweig-DiMenna Associates first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • Zweig-DiMenna Associates's Aegerion Pharmaceuticals position peaked at $36.1M in Q3 2013.
  • 99 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2015.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2015, filed 11 May 2015.